nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—PTGS2—colon cancer	0.398	1	CbGaD
Thalidomide—CYP2C9—Capecitabine—colon cancer	0.0323	0.251	CbGbCtD
Thalidomide—CYP3A5—Irinotecan—colon cancer	0.0297	0.232	CbGbCtD
Thalidomide—CYP3A5—Vincristine—colon cancer	0.026	0.202	CbGbCtD
Thalidomide—CYP1A2—Fluorouracil—colon cancer	0.0212	0.165	CbGbCtD
Thalidomide—CYP2C9—Fluorouracil—colon cancer	0.0191	0.149	CbGbCtD
Thalidomide—TNF—vagina—colon cancer	0.00337	0.0458	CbGeAlD
Thalidomide—CRBN—embryo—colon cancer	0.00294	0.04	CbGeAlD
Thalidomide—NFKB1—renal system—colon cancer	0.00265	0.0361	CbGeAlD
Thalidomide—FGFR2—embryo—colon cancer	0.00263	0.0358	CbGeAlD
Thalidomide—CRBN—renal system—colon cancer	0.00222	0.0302	CbGeAlD
Thalidomide—NFKB1—lymphoid tissue—colon cancer	0.0022	0.03	CbGeAlD
Thalidomide—TNF—lymph node—colon cancer	0.00218	0.0297	CbGeAlD
Thalidomide—NFKB1—digestive system—colon cancer	0.00217	0.0296	CbGeAlD
Thalidomide—FGFR2—epithelium—colon cancer	0.00215	0.0292	CbGeAlD
Thalidomide—FGFR2—smooth muscle tissue—colon cancer	0.00207	0.0282	CbGeAlD
Thalidomide—NFKB1—bone marrow—colon cancer	0.002	0.0273	CbGeAlD
Thalidomide—FGFR2—renal system—colon cancer	0.00199	0.0271	CbGeAlD
Thalidomide—NFKB1—vagina—colon cancer	0.00192	0.0261	CbGeAlD
Thalidomide—CRBN—lymphoid tissue—colon cancer	0.00184	0.0251	CbGeAlD
Thalidomide—CRBN—digestive system—colon cancer	0.00182	0.0248	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—colon cancer	0.00171	0.28	CrCbGaD
Thalidomide—CRBN—bone marrow—colon cancer	0.00168	0.0229	CbGeAlD
Thalidomide—FGFR2—digestive system—colon cancer	0.00163	0.0222	CbGeAlD
Thalidomide—NFKB1—liver—colon cancer	0.00162	0.022	CbGeAlD
Thalidomide—CRBN—vagina—colon cancer	0.00161	0.0219	CbGeAlD
Thalidomide—Pomalidomide—PTGS2—colon cancer	0.00159	0.26	CrCbGaD
Thalidomide—PTGS1—endothelium—colon cancer	0.00152	0.0207	CbGeAlD
Thalidomide—Lenalidomide—ABCB1—colon cancer	0.00146	0.238	CrCbGaD
Thalidomide—PTGS2—endothelium—colon cancer	0.00145	0.0198	CbGeAlD
Thalidomide—PTGS1—blood vessel—colon cancer	0.0014	0.0191	CbGeAlD
Thalidomide—CRBN—liver—colon cancer	0.00136	0.0185	CbGeAlD
Thalidomide—Pomalidomide—ABCB1—colon cancer	0.00135	0.221	CrCbGaD
Thalidomide—PTGS2—blood vessel—colon cancer	0.00134	0.0182	CbGeAlD
Thalidomide—PTGS2—gall bladder—colon cancer	0.00126	0.0172	CbGeAlD
Thalidomide—NFKB1—lymph node—colon cancer	0.00124	0.0169	CbGeAlD
Thalidomide—FGFR2—liver—colon cancer	0.00122	0.0166	CbGeAlD
Thalidomide—CRBN—lymph node—colon cancer	0.00104	0.0142	CbGeAlD
Thalidomide—PTGS2—embryo—colon cancer	0.000799	0.0109	CbGeAlD
Thalidomide—CYP1A1—epithelium—colon cancer	0.000777	0.0106	CbGeAlD
Thalidomide—CYP2C19—digestive system—colon cancer	0.000733	0.00998	CbGeAlD
Thalidomide—CYP1A2—renal system—colon cancer	0.00073	0.00994	CbGeAlD
Thalidomide—CYP1A1—renal system—colon cancer	0.00072	0.00981	CbGeAlD
Thalidomide—CYP3A5—renal system—colon cancer	0.000704	0.00959	CbGeAlD
Thalidomide—PTGS1—epithelium—colon cancer	0.000682	0.00929	CbGeAlD
Thalidomide—PTGS1—smooth muscle tissue—colon cancer	0.000657	0.00895	CbGeAlD
Thalidomide—CYP2E1—renal system—colon cancer	0.000657	0.00894	CbGeAlD
Thalidomide—PTGS2—epithelium—colon cancer	0.000652	0.00888	CbGeAlD
Thalidomide—CYP2C19—vagina—colon cancer	0.000648	0.00882	CbGeAlD
Thalidomide—PTGS1—renal system—colon cancer	0.000633	0.00862	CbGeAlD
Thalidomide—PTGS2—smooth muscle tissue—colon cancer	0.000628	0.00856	CbGeAlD
Thalidomide—PTGS2—renal system—colon cancer	0.000605	0.00824	CbGeAlD
Thalidomide—CYP1A2—digestive system—colon cancer	0.000599	0.00816	CbGeAlD
Thalidomide—CYP1A1—digestive system—colon cancer	0.000591	0.00804	CbGeAlD
Thalidomide—CYP3A5—digestive system—colon cancer	0.000578	0.00787	CbGeAlD
Thalidomide—CYP2C9—digestive system—colon cancer	0.000569	0.00774	CbGeAlD
Thalidomide—CYP2C19—liver—colon cancer	0.000546	0.00744	CbGeAlD
Thalidomide—CYP2E1—lymphoid tissue—colon cancer	0.000545	0.00743	CbGeAlD
Thalidomide—CYP2E1—digestive system—colon cancer	0.000539	0.00734	CbGeAlD
Thalidomide—CYP1A1—vagina—colon cancer	0.000522	0.0071	CbGeAlD
Thalidomide—PTGS1—digestive system—colon cancer	0.000519	0.00707	CbGeAlD
Thalidomide—CYP3A5—vagina—colon cancer	0.00051	0.00695	CbGeAlD
Thalidomide—PTGS2—lymphoid tissue—colon cancer	0.000502	0.00684	CbGeAlD
Thalidomide—PTGS2—digestive system—colon cancer	0.000496	0.00676	CbGeAlD
Thalidomide—PTGS1—vagina—colon cancer	0.000458	0.00624	CbGeAlD
Thalidomide—PTGS2—bone marrow—colon cancer	0.000457	0.00623	CbGeAlD
Thalidomide—CYP1A2—liver—colon cancer	0.000446	0.00608	CbGeAlD
Thalidomide—CYP1A1—liver—colon cancer	0.00044	0.00599	CbGeAlD
Thalidomide—PTGS2—vagina—colon cancer	0.000438	0.00597	CbGeAlD
Thalidomide—CYP3A5—liver—colon cancer	0.00043	0.00586	CbGeAlD
Thalidomide—CYP2C9—liver—colon cancer	0.000424	0.00577	CbGeAlD
Thalidomide—CYP2E1—liver—colon cancer	0.000401	0.00547	CbGeAlD
Thalidomide—PTGS2—liver—colon cancer	0.00037	0.00503	CbGeAlD
Thalidomide—CYP1A1—lymph node—colon cancer	0.000337	0.0046	CbGeAlD
Thalidomide—PTGS1—lymph node—colon cancer	0.000296	0.00404	CbGeAlD
Thalidomide—PTGS2—lymph node—colon cancer	0.000283	0.00386	CbGeAlD
Thalidomide—Shock—Irinotecan—colon cancer	0.000183	0.000763	CcSEcCtD
Thalidomide—Nervous system disorder—Irinotecan—colon cancer	0.000182	0.00076	CcSEcCtD
Thalidomide—Agranulocytosis—Capecitabine—colon cancer	0.000182	0.000759	CcSEcCtD
Thalidomide—Thrombocytopenia—Irinotecan—colon cancer	0.000182	0.000759	CcSEcCtD
Thalidomide—Anorexia—Vincristine—colon cancer	0.000182	0.000759	CcSEcCtD
Thalidomide—Hyperhidrosis—Irinotecan—colon cancer	0.00018	0.000749	CcSEcCtD
Thalidomide—Confusional state—Fluorouracil—colon cancer	0.00018	0.000749	CcSEcCtD
Thalidomide—Mood swings—Methotrexate—colon cancer	0.000179	0.000744	CcSEcCtD
Thalidomide—Hypotension—Vincristine—colon cancer	0.000178	0.000744	CcSEcCtD
Thalidomide—Bradycardia—Capecitabine—colon cancer	0.000178	0.000743	CcSEcCtD
Thalidomide—Oedema—Fluorouracil—colon cancer	0.000178	0.000742	CcSEcCtD
Thalidomide—Anorexia—Irinotecan—colon cancer	0.000177	0.000739	CcSEcCtD
Thalidomide—Ataxia—Methotrexate—colon cancer	0.000177	0.000739	CcSEcCtD
Thalidomide—Infection—Fluorouracil—colon cancer	0.000177	0.000738	CcSEcCtD
Thalidomide—Rhinitis—Capecitabine—colon cancer	0.000176	0.000732	CcSEcCtD
Thalidomide—Hepatitis—Capecitabine—colon cancer	0.000175	0.00073	CcSEcCtD
Thalidomide—Nervous system disorder—Fluorouracil—colon cancer	0.000175	0.000728	CcSEcCtD
Thalidomide—Thrombocytopenia—Fluorouracil—colon cancer	0.000174	0.000727	CcSEcCtD
Thalidomide—Hypoaesthesia—Capecitabine—colon cancer	0.000174	0.000727	CcSEcCtD
Thalidomide—Liver function test abnormal—Methotrexate—colon cancer	0.000174	0.000726	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Vincristine—colon cancer	0.000174	0.000725	CcSEcCtD
Thalidomide—Pharyngitis—Capecitabine—colon cancer	0.000174	0.000725	CcSEcCtD
Thalidomide—Tachycardia—Fluorouracil—colon cancer	0.000174	0.000725	CcSEcCtD
Thalidomide—Hypotension—Irinotecan—colon cancer	0.000174	0.000724	CcSEcCtD
Thalidomide—Urinary tract disorder—Capecitabine—colon cancer	0.000173	0.000721	CcSEcCtD
Thalidomide—Insomnia—Vincristine—colon cancer	0.000173	0.00072	CcSEcCtD
Thalidomide—Oedema peripheral—Capecitabine—colon cancer	0.000173	0.000719	CcSEcCtD
Thalidomide—Urethral disorder—Capecitabine—colon cancer	0.000172	0.000716	CcSEcCtD
Thalidomide—Paraesthesia—Vincristine—colon cancer	0.000171	0.000715	CcSEcCtD
Thalidomide—Breast disorder—Methotrexate—colon cancer	0.00017	0.00071	CcSEcCtD
Thalidomide—Anorexia—Fluorouracil—colon cancer	0.00017	0.000708	CcSEcCtD
Thalidomide—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.00017	0.000708	CcSEcCtD
Thalidomide—Visual impairment—Capecitabine—colon cancer	0.000169	0.000704	CcSEcCtD
Thalidomide—Insomnia—Irinotecan—colon cancer	0.000168	0.000701	CcSEcCtD
Thalidomide—Paraesthesia—Irinotecan—colon cancer	0.000167	0.000696	CcSEcCtD
Thalidomide—Hypotension—Fluorouracil—colon cancer	0.000166	0.000694	CcSEcCtD
Thalidomide—Decreased appetite—Vincristine—colon cancer	0.000166	0.000692	CcSEcCtD
Thalidomide—Dyspnoea—Irinotecan—colon cancer	0.000166	0.000691	CcSEcCtD
Thalidomide—Erythema multiforme—Capecitabine—colon cancer	0.000166	0.000691	CcSEcCtD
Thalidomide—Somnolence—Irinotecan—colon cancer	0.000165	0.000689	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Vincristine—colon cancer	0.000165	0.000687	CcSEcCtD
Thalidomide—Fatigue—Vincristine—colon cancer	0.000165	0.000686	CcSEcCtD
Thalidomide—Eye disorder—Capecitabine—colon cancer	0.000164	0.000682	CcSEcCtD
Thalidomide—Dyspepsia—Irinotecan—colon cancer	0.000164	0.000682	CcSEcCtD
Thalidomide—Tinnitus—Capecitabine—colon cancer	0.000163	0.000681	CcSEcCtD
Thalidomide—Constipation—Vincristine—colon cancer	0.000163	0.000681	CcSEcCtD
Thalidomide—Pain—Vincristine—colon cancer	0.000163	0.000681	CcSEcCtD
Thalidomide—Cardiac disorder—Capecitabine—colon cancer	0.000163	0.000678	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000162	0.000676	CcSEcCtD
Thalidomide—Decreased appetite—Irinotecan—colon cancer	0.000162	0.000674	CcSEcCtD
Thalidomide—Eosinophilia—Methotrexate—colon cancer	0.000161	0.000672	CcSEcCtD
Thalidomide—Insomnia—Fluorouracil—colon cancer	0.000161	0.000672	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Irinotecan—colon cancer	0.000161	0.000669	CcSEcCtD
Thalidomide—Fatigue—Irinotecan—colon cancer	0.00016	0.000668	CcSEcCtD
Thalidomide—Paraesthesia—Fluorouracil—colon cancer	0.00016	0.000667	CcSEcCtD
Thalidomide—Pancreatitis—Methotrexate—colon cancer	0.00016	0.000666	CcSEcCtD
Thalidomide—Pain—Irinotecan—colon cancer	0.000159	0.000663	CcSEcCtD
Thalidomide—Constipation—Irinotecan—colon cancer	0.000159	0.000663	CcSEcCtD
Thalidomide—Angiopathy—Capecitabine—colon cancer	0.000159	0.000663	CcSEcCtD
Thalidomide—Dyspnoea—Fluorouracil—colon cancer	0.000159	0.000662	CcSEcCtD
Thalidomide—Somnolence—Fluorouracil—colon cancer	0.000158	0.00066	CcSEcCtD
Thalidomide—Immune system disorder—Capecitabine—colon cancer	0.000158	0.00066	CcSEcCtD
Thalidomide—Mediastinal disorder—Capecitabine—colon cancer	0.000158	0.000658	CcSEcCtD
Thalidomide—Chills—Capecitabine—colon cancer	0.000157	0.000655	CcSEcCtD
Thalidomide—Dyspepsia—Fluorouracil—colon cancer	0.000157	0.000654	CcSEcCtD
Thalidomide—Arrhythmia—Capecitabine—colon cancer	0.000157	0.000652	CcSEcCtD
Thalidomide—Gastrointestinal pain—Vincristine—colon cancer	0.000156	0.000651	CcSEcCtD
Thalidomide—Decreased appetite—Fluorouracil—colon cancer	0.000155	0.000645	CcSEcCtD
Thalidomide—Alopecia—Capecitabine—colon cancer	0.000155	0.000645	CcSEcCtD
Thalidomide—Pancytopenia—Methotrexate—colon cancer	0.000155	0.000645	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000154	0.000641	CcSEcCtD
Thalidomide—Mental disorder—Capecitabine—colon cancer	0.000153	0.00064	CcSEcCtD
Thalidomide—Feeling abnormal—Irinotecan—colon cancer	0.000153	0.000639	CcSEcCtD
Thalidomide—Malnutrition—Capecitabine—colon cancer	0.000153	0.000636	CcSEcCtD
Thalidomide—Neutropenia—Methotrexate—colon cancer	0.000152	0.000635	CcSEcCtD
Thalidomide—Pain—Fluorouracil—colon cancer	0.000152	0.000635	CcSEcCtD
Thalidomide—Gastrointestinal pain—Irinotecan—colon cancer	0.000152	0.000634	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Methotrexate—colon cancer	0.000151	0.000631	CcSEcCtD
Thalidomide—Body temperature increased—Vincristine—colon cancer	0.000151	0.000629	CcSEcCtD
Thalidomide—Abdominal pain—Vincristine—colon cancer	0.000151	0.000629	CcSEcCtD
Thalidomide—Flatulence—Capecitabine—colon cancer	0.00015	0.000626	CcSEcCtD
Thalidomide—Erectile dysfunction—Methotrexate—colon cancer	0.00015	0.000626	CcSEcCtD
Thalidomide—Dysgeusia—Capecitabine—colon cancer	0.000149	0.000623	CcSEcCtD
Thalidomide—Photosensitivity reaction—Methotrexate—colon cancer	0.000149	0.00062	CcSEcCtD
Thalidomide—Back pain—Capecitabine—colon cancer	0.000148	0.000615	CcSEcCtD
Thalidomide—Abdominal pain—Irinotecan—colon cancer	0.000147	0.000613	CcSEcCtD
Thalidomide—Body temperature increased—Irinotecan—colon cancer	0.000147	0.000613	CcSEcCtD
Thalidomide—Feeling abnormal—Fluorouracil—colon cancer	0.000147	0.000612	CcSEcCtD
Thalidomide—Muscle spasms—Capecitabine—colon cancer	0.000147	0.000611	CcSEcCtD
Thalidomide—Pneumonia—Methotrexate—colon cancer	0.000146	0.000609	CcSEcCtD
Thalidomide—Drowsiness—Methotrexate—colon cancer	0.000145	0.000606	CcSEcCtD
Thalidomide—Infestation NOS—Methotrexate—colon cancer	0.000145	0.000606	CcSEcCtD
Thalidomide—Infestation—Methotrexate—colon cancer	0.000145	0.000606	CcSEcCtD
Thalidomide—Depression—Methotrexate—colon cancer	0.000145	0.000604	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000144	0.0006	CcSEcCtD
Thalidomide—Vision blurred—Capecitabine—colon cancer	0.000144	0.000599	CcSEcCtD
Thalidomide—Tremor—Capecitabine—colon cancer	0.000143	0.000596	CcSEcCtD
Thalidomide—Renal failure—Methotrexate—colon cancer	0.000143	0.000595	CcSEcCtD
Thalidomide—Stomatitis—Methotrexate—colon cancer	0.000142	0.00059	CcSEcCtD
Thalidomide—Ill-defined disorder—Capecitabine—colon cancer	0.000142	0.00059	CcSEcCtD
Thalidomide—Urticaria—Fluorouracil—colon cancer	0.000142	0.00059	CcSEcCtD
Thalidomide—Conjunctivitis—Methotrexate—colon cancer	0.000141	0.000589	CcSEcCtD
Thalidomide—Anaemia—Capecitabine—colon cancer	0.000141	0.000588	CcSEcCtD
Thalidomide—Body temperature increased—Fluorouracil—colon cancer	0.000141	0.000587	CcSEcCtD
Thalidomide—Hypersensitivity—Vincristine—colon cancer	0.000141	0.000586	CcSEcCtD
Thalidomide—Sweating—Methotrexate—colon cancer	0.000139	0.000581	CcSEcCtD
Thalidomide—Haematuria—Methotrexate—colon cancer	0.000139	0.000577	CcSEcCtD
Thalidomide—Malaise—Capecitabine—colon cancer	0.000138	0.000573	CcSEcCtD
Thalidomide—Epistaxis—Methotrexate—colon cancer	0.000137	0.000571	CcSEcCtD
Thalidomide—Vertigo—Capecitabine—colon cancer	0.000137	0.000571	CcSEcCtD
Thalidomide—Hypersensitivity—Irinotecan—colon cancer	0.000137	0.000571	CcSEcCtD
Thalidomide—Asthenia—Vincristine—colon cancer	0.000137	0.000571	CcSEcCtD
Thalidomide—Syncope—Capecitabine—colon cancer	0.000137	0.00057	CcSEcCtD
Thalidomide—Leukopenia—Capecitabine—colon cancer	0.000137	0.000569	CcSEcCtD
Thalidomide—Agranulocytosis—Methotrexate—colon cancer	0.000136	0.000565	CcSEcCtD
Thalidomide—Palpitations—Capecitabine—colon cancer	0.000135	0.000562	CcSEcCtD
Thalidomide—Loss of consciousness—Capecitabine—colon cancer	0.000134	0.000559	CcSEcCtD
Thalidomide—Asthenia—Irinotecan—colon cancer	0.000133	0.000556	CcSEcCtD
Thalidomide—Cough—Capecitabine—colon cancer	0.000133	0.000555	CcSEcCtD
Thalidomide—Hypertension—Capecitabine—colon cancer	0.000132	0.000549	CcSEcCtD
Thalidomide—Hypersensitivity—Fluorouracil—colon cancer	0.000131	0.000547	CcSEcCtD
Thalidomide—Diarrhoea—Vincristine—colon cancer	0.000131	0.000545	CcSEcCtD
Thalidomide—Hepatitis—Methotrexate—colon cancer	0.00013	0.000544	CcSEcCtD
Thalidomide—Chest pain—Capecitabine—colon cancer	0.00013	0.000541	CcSEcCtD
Thalidomide—Arthralgia—Capecitabine—colon cancer	0.00013	0.000541	CcSEcCtD
Thalidomide—Myalgia—Capecitabine—colon cancer	0.00013	0.000541	CcSEcCtD
Thalidomide—Pharyngitis—Methotrexate—colon cancer	0.000129	0.00054	CcSEcCtD
Thalidomide—Anxiety—Capecitabine—colon cancer	0.000129	0.000539	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000129	0.000538	CcSEcCtD
Thalidomide—Urinary tract disorder—Methotrexate—colon cancer	0.000129	0.000537	CcSEcCtD
Thalidomide—Discomfort—Capecitabine—colon cancer	0.000128	0.000535	CcSEcCtD
Thalidomide—Urethral disorder—Methotrexate—colon cancer	0.000128	0.000533	CcSEcCtD
Thalidomide—Diarrhoea—Irinotecan—colon cancer	0.000127	0.00053	CcSEcCtD
Thalidomide—Dry mouth—Capecitabine—colon cancer	0.000127	0.000529	CcSEcCtD
Thalidomide—Dizziness—Vincristine—colon cancer	0.000126	0.000526	CcSEcCtD
Thalidomide—Pruritus—Fluorouracil—colon cancer	0.000126	0.000525	CcSEcCtD
Thalidomide—Visual impairment—Methotrexate—colon cancer	0.000126	0.000524	CcSEcCtD
Thalidomide—Confusional state—Capecitabine—colon cancer	0.000126	0.000523	CcSEcCtD
Thalidomide—Oedema—Capecitabine—colon cancer	0.000124	0.000519	CcSEcCtD
Thalidomide—Infection—Capecitabine—colon cancer	0.000124	0.000515	CcSEcCtD
Thalidomide—Erythema multiforme—Methotrexate—colon cancer	0.000123	0.000514	CcSEcCtD
Thalidomide—Dizziness—Irinotecan—colon cancer	0.000123	0.000513	CcSEcCtD
Thalidomide—Shock—Capecitabine—colon cancer	0.000122	0.00051	CcSEcCtD
Thalidomide—Nervous system disorder—Capecitabine—colon cancer	0.000122	0.000509	CcSEcCtD
Thalidomide—Eye disorder—Methotrexate—colon cancer	0.000122	0.000508	CcSEcCtD
Thalidomide—Diarrhoea—Fluorouracil—colon cancer	0.000122	0.000508	CcSEcCtD
Thalidomide—Thrombocytopenia—Capecitabine—colon cancer	0.000122	0.000508	CcSEcCtD
Thalidomide—Tinnitus—Methotrexate—colon cancer	0.000122	0.000507	CcSEcCtD
Thalidomide—Tachycardia—Capecitabine—colon cancer	0.000121	0.000506	CcSEcCtD
Thalidomide—Vomiting—Vincristine—colon cancer	0.000121	0.000506	CcSEcCtD
Thalidomide—Cardiac disorder—Methotrexate—colon cancer	0.000121	0.000505	CcSEcCtD
Thalidomide—Skin disorder—Capecitabine—colon cancer	0.000121	0.000504	CcSEcCtD
Thalidomide—Rash—Vincristine—colon cancer	0.00012	0.000502	CcSEcCtD
Thalidomide—Hyperhidrosis—Capecitabine—colon cancer	0.00012	0.000502	CcSEcCtD
Thalidomide—Dermatitis—Vincristine—colon cancer	0.00012	0.000501	CcSEcCtD
Thalidomide—Headache—Vincristine—colon cancer	0.00012	0.000499	CcSEcCtD
Thalidomide—Anorexia—Capecitabine—colon cancer	0.000119	0.000495	CcSEcCtD
Thalidomide—Angiopathy—Methotrexate—colon cancer	0.000118	0.000493	CcSEcCtD
Thalidomide—Vomiting—Irinotecan—colon cancer	0.000118	0.000493	CcSEcCtD
Thalidomide—Immune system disorder—Methotrexate—colon cancer	0.000118	0.000491	CcSEcCtD
Thalidomide—Dizziness—Fluorouracil—colon cancer	0.000118	0.000491	CcSEcCtD
Thalidomide—Mediastinal disorder—Methotrexate—colon cancer	0.000118	0.00049	CcSEcCtD
Thalidomide—Rash—Irinotecan—colon cancer	0.000117	0.000489	CcSEcCtD
Thalidomide—Dermatitis—Irinotecan—colon cancer	0.000117	0.000488	CcSEcCtD
Thalidomide—Chills—Methotrexate—colon cancer	0.000117	0.000488	CcSEcCtD
Thalidomide—Headache—Irinotecan—colon cancer	0.000117	0.000486	CcSEcCtD
Thalidomide—Hypotension—Capecitabine—colon cancer	0.000116	0.000485	CcSEcCtD
Thalidomide—Alopecia—Methotrexate—colon cancer	0.000115	0.00048	CcSEcCtD
Thalidomide—Mental disorder—Methotrexate—colon cancer	0.000114	0.000476	CcSEcCtD
Thalidomide—Malnutrition—Methotrexate—colon cancer	0.000114	0.000473	CcSEcCtD
Thalidomide—Nausea—Vincristine—colon cancer	0.000113	0.000473	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000113	0.000473	CcSEcCtD
Thalidomide—Vomiting—Fluorouracil—colon cancer	0.000113	0.000472	CcSEcCtD
Thalidomide—Insomnia—Capecitabine—colon cancer	0.000113	0.000469	CcSEcCtD
Thalidomide—Rash—Fluorouracil—colon cancer	0.000112	0.000468	CcSEcCtD
Thalidomide—Dermatitis—Fluorouracil—colon cancer	0.000112	0.000468	CcSEcCtD
Thalidomide—Paraesthesia—Capecitabine—colon cancer	0.000112	0.000466	CcSEcCtD
Thalidomide—Headache—Fluorouracil—colon cancer	0.000112	0.000465	CcSEcCtD
Thalidomide—Dysgeusia—Methotrexate—colon cancer	0.000111	0.000463	CcSEcCtD
Thalidomide—Dyspnoea—Capecitabine—colon cancer	0.000111	0.000463	CcSEcCtD
Thalidomide—Nausea—Irinotecan—colon cancer	0.00011	0.00046	CcSEcCtD
Thalidomide—Back pain—Methotrexate—colon cancer	0.00011	0.000458	CcSEcCtD
Thalidomide—Dyspepsia—Capecitabine—colon cancer	0.00011	0.000457	CcSEcCtD
Thalidomide—Decreased appetite—Capecitabine—colon cancer	0.000108	0.000451	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Capecitabine—colon cancer	0.000107	0.000448	CcSEcCtD
Thalidomide—Fatigue—Capecitabine—colon cancer	0.000107	0.000447	CcSEcCtD
Thalidomide—Vision blurred—Methotrexate—colon cancer	0.000107	0.000446	CcSEcCtD
Thalidomide—Pain—Capecitabine—colon cancer	0.000106	0.000444	CcSEcCtD
Thalidomide—Constipation—Capecitabine—colon cancer	0.000106	0.000444	CcSEcCtD
Thalidomide—Nausea—Fluorouracil—colon cancer	0.000106	0.000441	CcSEcCtD
Thalidomide—Ill-defined disorder—Methotrexate—colon cancer	0.000105	0.000439	CcSEcCtD
Thalidomide—Anaemia—Methotrexate—colon cancer	0.000105	0.000437	CcSEcCtD
Thalidomide—Feeling abnormal—Capecitabine—colon cancer	0.000103	0.000428	CcSEcCtD
Thalidomide—Malaise—Methotrexate—colon cancer	0.000102	0.000427	CcSEcCtD
Thalidomide—Vertigo—Methotrexate—colon cancer	0.000102	0.000425	CcSEcCtD
Thalidomide—Gastrointestinal pain—Capecitabine—colon cancer	0.000102	0.000424	CcSEcCtD
Thalidomide—Leukopenia—Methotrexate—colon cancer	0.000102	0.000424	CcSEcCtD
Thalidomide—Cough—Methotrexate—colon cancer	9.91e-05	0.000413	CcSEcCtD
Thalidomide—Urticaria—Capecitabine—colon cancer	9.89e-05	0.000412	CcSEcCtD
Thalidomide—Abdominal pain—Capecitabine—colon cancer	9.84e-05	0.00041	CcSEcCtD
Thalidomide—Body temperature increased—Capecitabine—colon cancer	9.84e-05	0.00041	CcSEcCtD
Thalidomide—Convulsion—Methotrexate—colon cancer	9.84e-05	0.00041	CcSEcCtD
Thalidomide—Chest pain—Methotrexate—colon cancer	9.67e-05	0.000403	CcSEcCtD
Thalidomide—Arthralgia—Methotrexate—colon cancer	9.67e-05	0.000403	CcSEcCtD
Thalidomide—Myalgia—Methotrexate—colon cancer	9.67e-05	0.000403	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	9.6e-05	0.0004	CcSEcCtD
Thalidomide—Discomfort—Methotrexate—colon cancer	9.55e-05	0.000398	CcSEcCtD
Thalidomide—Confusional state—Methotrexate—colon cancer	9.34e-05	0.000389	CcSEcCtD
Thalidomide—Infection—Methotrexate—colon cancer	9.21e-05	0.000384	CcSEcCtD
Thalidomide—Hypersensitivity—Capecitabine—colon cancer	9.17e-05	0.000382	CcSEcCtD
Thalidomide—Nervous system disorder—Methotrexate—colon cancer	9.09e-05	0.000379	CcSEcCtD
Thalidomide—Thrombocytopenia—Methotrexate—colon cancer	9.07e-05	0.000378	CcSEcCtD
Thalidomide—Skin disorder—Methotrexate—colon cancer	9e-05	0.000375	CcSEcCtD
Thalidomide—Hyperhidrosis—Methotrexate—colon cancer	8.96e-05	0.000373	CcSEcCtD
Thalidomide—Asthenia—Capecitabine—colon cancer	8.93e-05	0.000372	CcSEcCtD
Thalidomide—Anorexia—Methotrexate—colon cancer	8.83e-05	0.000368	CcSEcCtD
Thalidomide—Pruritus—Capecitabine—colon cancer	8.81e-05	0.000367	CcSEcCtD
Thalidomide—Hypotension—Methotrexate—colon cancer	8.66e-05	0.000361	CcSEcCtD
Thalidomide—Diarrhoea—Capecitabine—colon cancer	8.52e-05	0.000355	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Methotrexate—colon cancer	8.44e-05	0.000352	CcSEcCtD
Thalidomide—Insomnia—Methotrexate—colon cancer	8.38e-05	0.000349	CcSEcCtD
Thalidomide—Paraesthesia—Methotrexate—colon cancer	8.32e-05	0.000347	CcSEcCtD
Thalidomide—Dyspnoea—Methotrexate—colon cancer	8.26e-05	0.000344	CcSEcCtD
Thalidomide—Somnolence—Methotrexate—colon cancer	8.24e-05	0.000343	CcSEcCtD
Thalidomide—Dizziness—Capecitabine—colon cancer	8.23e-05	0.000343	CcSEcCtD
Thalidomide—Dyspepsia—Methotrexate—colon cancer	8.16e-05	0.00034	CcSEcCtD
Thalidomide—Decreased appetite—Methotrexate—colon cancer	8.05e-05	0.000336	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Methotrexate—colon cancer	8e-05	0.000333	CcSEcCtD
Thalidomide—Fatigue—Methotrexate—colon cancer	7.99e-05	0.000333	CcSEcCtD
Thalidomide—Pain—Methotrexate—colon cancer	7.92e-05	0.00033	CcSEcCtD
Thalidomide—Vomiting—Capecitabine—colon cancer	7.91e-05	0.00033	CcSEcCtD
Thalidomide—Rash—Capecitabine—colon cancer	7.85e-05	0.000327	CcSEcCtD
Thalidomide—Dermatitis—Capecitabine—colon cancer	7.84e-05	0.000327	CcSEcCtD
Thalidomide—Headache—Capecitabine—colon cancer	7.8e-05	0.000325	CcSEcCtD
Thalidomide—Feeling abnormal—Methotrexate—colon cancer	7.64e-05	0.000318	CcSEcCtD
Thalidomide—Gastrointestinal pain—Methotrexate—colon cancer	7.58e-05	0.000316	CcSEcCtD
Thalidomide—Nausea—Capecitabine—colon cancer	7.39e-05	0.000308	CcSEcCtD
Thalidomide—Urticaria—Methotrexate—colon cancer	7.36e-05	0.000307	CcSEcCtD
Thalidomide—Abdominal pain—Methotrexate—colon cancer	7.32e-05	0.000305	CcSEcCtD
Thalidomide—Body temperature increased—Methotrexate—colon cancer	7.32e-05	0.000305	CcSEcCtD
Thalidomide—Hypersensitivity—Methotrexate—colon cancer	6.83e-05	0.000285	CcSEcCtD
Thalidomide—Asthenia—Methotrexate—colon cancer	6.65e-05	0.000277	CcSEcCtD
Thalidomide—Pruritus—Methotrexate—colon cancer	6.56e-05	0.000273	CcSEcCtD
Thalidomide—Diarrhoea—Methotrexate—colon cancer	6.34e-05	0.000264	CcSEcCtD
Thalidomide—Dizziness—Methotrexate—colon cancer	6.13e-05	0.000255	CcSEcCtD
Thalidomide—Vomiting—Methotrexate—colon cancer	5.89e-05	0.000246	CcSEcCtD
Thalidomide—Rash—Methotrexate—colon cancer	5.84e-05	0.000244	CcSEcCtD
Thalidomide—Dermatitis—Methotrexate—colon cancer	5.84e-05	0.000243	CcSEcCtD
Thalidomide—Headache—Methotrexate—colon cancer	5.8e-05	0.000242	CcSEcCtD
Thalidomide—Nausea—Methotrexate—colon cancer	5.5e-05	0.000229	CcSEcCtD
Thalidomide—NFKB1—Signaling by NGF—HRAS—colon cancer	4.06e-05	0.000264	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	4.06e-05	0.000264	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CHST5—colon cancer	3.96e-05	0.000257	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ODC1—colon cancer	3.96e-05	0.000257	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CD8A—colon cancer	3.95e-05	0.000257	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	3.86e-05	0.000251	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—HRAS—colon cancer	3.85e-05	0.000251	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—EP300—colon cancer	3.83e-05	0.00025	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	3.77e-05	0.000246	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	3.76e-05	0.000245	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—SRC—colon cancer	3.73e-05	0.000243	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	3.66e-05	0.000238	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CTNNB1—colon cancer	3.64e-05	0.000237	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—VEGFA—colon cancer	3.63e-05	0.000236	CbGpPWpGaD
Thalidomide—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—colon cancer	3.6e-05	0.000234	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—AKT1—colon cancer	3.59e-05	0.000233	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—NRAS—colon cancer	3.59e-05	0.000233	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—CDKN1A—colon cancer	3.56e-05	0.000232	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—BCL2L1—colon cancer	3.56e-05	0.000232	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CTNNB1—colon cancer	3.46e-05	0.000225	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—CDKN1A—colon cancer	3.42e-05	0.000222	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—AKT1—colon cancer	3.4e-05	0.000222	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—FGFR3—colon cancer	3.4e-05	0.000221	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—EP300—colon cancer	3.39e-05	0.00022	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ODC1—colon cancer	3.38e-05	0.00022	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CHST5—colon cancer	3.38e-05	0.00022	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—CDKN1A—colon cancer	3.38e-05	0.00022	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—BCL2L1—colon cancer	3.38e-05	0.00022	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	3.37e-05	0.000219	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	3.36e-05	0.000219	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—TGFB1—colon cancer	3.33e-05	0.000217	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	3.29e-05	0.000214	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—SRC—colon cancer	3.29e-05	0.000214	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—EGFR—colon cancer	3.27e-05	0.000213	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—CDKN1A—colon cancer	3.24e-05	0.000211	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—FGFR3—colon cancer	3.23e-05	0.00021	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—EP300—colon cancer	3.21e-05	0.000209	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—NRAS—colon cancer	3.17e-05	0.000206	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—SRC—colon cancer	3.16e-05	0.000206	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—CTNNB1—colon cancer	3.14e-05	0.000205	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—SRC—colon cancer	3.12e-05	0.000203	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	3.11e-05	0.000202	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.11e-05	0.000202	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—KRAS—colon cancer	3.09e-05	0.000201	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—NRAS—colon cancer	3.04e-05	0.000198	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—NRAS—colon cancer	3.01e-05	0.000196	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—SRC—colon cancer	3e-05	0.000195	CbGpPWpGaD
Thalidomide—FGFR2—Disease—FGFR3—colon cancer	2.98e-05	0.000194	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—EP300—colon cancer	2.92e-05	0.00019	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—NRAS—colon cancer	2.89e-05	0.000188	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—EGFR—colon cancer	2.89e-05	0.000188	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CDH1—colon cancer	2.87e-05	0.000187	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	2.86e-05	0.000186	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—SRC—colon cancer	2.84e-05	0.000185	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—EGFR—colon cancer	2.77e-05	0.00018	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—VEGFA—colon cancer	2.77e-05	0.00018	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	2.76e-05	0.00018	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—EGFR—colon cancer	2.74e-05	0.000178	CbGpPWpGaD
Thalidomide—FGFR2—Disease—APC—colon cancer	2.74e-05	0.000178	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—NRAS—colon cancer	2.73e-05	0.000178	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CDH1—colon cancer	2.73e-05	0.000177	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—KRAS—colon cancer	2.73e-05	0.000177	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—EGFR—colon cancer	2.63e-05	0.000171	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—HRAS—colon cancer	2.62e-05	0.000171	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—KRAS—colon cancer	2.62e-05	0.00017	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—KRAS—colon cancer	2.59e-05	0.000168	CbGpPWpGaD
Thalidomide—FGFR2—Disease—BRAF—colon cancer	2.57e-05	0.000167	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—TGFB1—colon cancer	2.54e-05	0.000165	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—PIK3CA—colon cancer	2.5e-05	0.000163	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—EGFR—colon cancer	2.49e-05	0.000162	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—KRAS—colon cancer	2.48e-05	0.000162	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.47e-05	0.00016	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.44e-05	0.000159	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—PIK3CA—colon cancer	2.41e-05	0.000157	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—PIK3CA—colon cancer	2.38e-05	0.000155	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—KRAS—colon cancer	2.35e-05	0.000153	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	2.33e-05	0.000152	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—HRAS—colon cancer	2.32e-05	0.000151	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—AKT1—colon cancer	2.32e-05	0.000151	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—PIK3CA—colon cancer	2.28e-05	0.000149	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HRAS—colon cancer	2.23e-05	0.000145	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—FGFR3—colon cancer	2.2e-05	0.000143	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HRAS—colon cancer	2.2e-05	0.000143	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.19e-05	0.000142	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CTNNB1—colon cancer	2.12e-05	0.000138	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HRAS—colon cancer	2.11e-05	0.000137	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—FGFR3—colon cancer	2.09e-05	0.000136	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTGS2—colon cancer	2.08e-05	0.000135	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—CDKN1A—colon cancer	2.07e-05	0.000135	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—AKT1—colon cancer	2.05e-05	0.000133	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.03e-05	0.000132	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—APC—colon cancer	2.02e-05	0.000131	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CTNNB1—colon cancer	2.01e-05	0.000131	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—HRAS—colon cancer	2e-05	0.00013	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—ABCB1—colon cancer	1.99e-05	0.000129	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EP300—colon cancer	1.97e-05	0.000128	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CDKN1A—colon cancer	1.97e-05	0.000128	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—AKT1—colon cancer	1.96e-05	0.000128	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TYMS—colon cancer	1.95e-05	0.000127	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—AKT1—colon cancer	1.94e-05	0.000126	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—SRC—colon cancer	1.92e-05	0.000125	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APC—colon cancer	1.92e-05	0.000125	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—BRAF—colon cancer	1.9e-05	0.000124	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EP300—colon cancer	1.87e-05	0.000122	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—AKT1—colon cancer	1.86e-05	0.000121	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CTNNB1—colon cancer	1.86e-05	0.000121	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—NRAS—colon cancer	1.84e-05	0.00012	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—SRC—colon cancer	1.82e-05	0.000118	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CDKN1A—colon cancer	1.82e-05	0.000118	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—BRAF—colon cancer	1.8e-05	0.000117	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.79e-05	0.000117	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—AKT1—colon cancer	1.77e-05	0.000115	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—NRAS—colon cancer	1.75e-05	0.000114	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EP300—colon cancer	1.73e-05	0.000112	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.72e-05	0.000112	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—EGFR—colon cancer	1.68e-05	0.000109	CbGpPWpGaD
Thalidomide—FGFR2—Disease—SRC—colon cancer	1.68e-05	0.000109	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.63e-05	0.000106	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NRAS—colon cancer	1.62e-05	0.000105	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.61e-05	0.000105	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—EGFR—colon cancer	1.59e-05	0.000104	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KRAS—colon cancer	1.59e-05	0.000103	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ABCB1—colon cancer	1.58e-05	0.000103	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TYMS—colon cancer	1.55e-05	0.000101	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KRAS—colon cancer	1.51e-05	9.81e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—MYC—colon cancer	1.51e-05	9.8e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.5e-05	9.78e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFB1—colon cancer	1.5e-05	9.77e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ABCB1—colon cancer	1.49e-05	9.67e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ABCB1—colon cancer	1.48e-05	9.65e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—FGFR3—colon cancer	1.48e-05	9.63e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—EGFR—colon cancer	1.47e-05	9.58e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TYMS—colon cancer	1.46e-05	9.5e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PIK3CA—colon cancer	1.46e-05	9.49e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TYMS—colon cancer	1.46e-05	9.48e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.43e-05	9.32e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CASP3—colon cancer	1.42e-05	9.26e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.41e-05	9.17e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ABCB1—colon cancer	1.4e-05	9.12e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.4e-05	9.08e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KRAS—colon cancer	1.39e-05	9.05e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCND1—colon cancer	1.39e-05	9.01e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PIK3CA—colon cancer	1.38e-05	9.01e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARG—colon cancer	1.38e-05	9e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TYMS—colon cancer	1.38e-05	8.95e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CTNNB1—colon cancer	1.37e-05	8.93e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APC—colon cancer	1.36e-05	8.84e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CASP3—colon cancer	1.35e-05	8.79e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—colon cancer	1.35e-05	8.78e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDKN1A—colon cancer	1.34e-05	8.72e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCND1—colon cancer	1.31e-05	8.55e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CTNNB1—colon cancer	1.3e-05	8.47e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.28e-05	8.36e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HRAS—colon cancer	1.28e-05	8.33e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PIK3CA—colon cancer	1.28e-05	8.32e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—BRAF—colon cancer	1.28e-05	8.31e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EP300—colon cancer	1.27e-05	8.3e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDKN1A—colon cancer	1.27e-05	8.27e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SRC—colon cancer	1.24e-05	8.07e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EP300—colon cancer	1.21e-05	7.87e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—colon cancer	1.21e-05	7.86e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.19e-05	7.77e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NRAS—colon cancer	1.19e-05	7.76e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—colon cancer	1.19e-05	7.76e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—colon cancer	1.18e-05	7.69e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SRC—colon cancer	1.18e-05	7.66e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.17e-05	7.63e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ABCB1—colon cancer	1.15e-05	7.46e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—colon cancer	1.15e-05	7.46e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NRAS—colon cancer	1.13e-05	7.37e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—colon cancer	1.13e-05	7.36e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TYMS—colon cancer	1.13e-05	7.33e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MYC—colon cancer	1.11e-05	7.23e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—colon cancer	1.11e-05	7.21e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARG—colon cancer	1.1e-05	7.15e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.1e-05	7.14e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—colon cancer	1.09e-05	7.08e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—EGFR—colon cancer	1.09e-05	7.07e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.07e-05	6.95e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.06e-05	6.89e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MYC—colon cancer	1.05e-05	6.86e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—colon cancer	1.05e-05	6.84e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ABCB1—colon cancer	1.05e-05	6.8e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—colon cancer	1.04e-05	6.79e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARG—colon cancer	1.03e-05	6.73e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARG—colon cancer	1.03e-05	6.71e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—EGFR—colon cancer	1.03e-05	6.71e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KRAS—colon cancer	1.03e-05	6.68e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TYMS—colon cancer	1.03e-05	6.68e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARG—colon cancer	9.75e-06	6.34e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KRAS—colon cancer	9.74e-06	6.34e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PIK3CA—colon cancer	9.43e-06	6.14e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CTNNB1—colon cancer	9.23e-06	6.01e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	9.13e-06	5.94e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—colon cancer	9.12e-06	5.94e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—EP300—colon cancer	9.05e-06	5.89e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDKN1A—colon cancer	9.02e-06	5.87e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PIK3CA—colon cancer	8.95e-06	5.82e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ABCB1—colon cancer	8.93e-06	5.81e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TYMS—colon cancer	8.77e-06	5.71e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—colon cancer	8.73e-06	5.68e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	8.67e-06	5.64e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—colon cancer	8.66e-06	5.63e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EP300—colon cancer	8.58e-06	5.58e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—SRC—colon cancer	8.34e-06	5.43e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—colon cancer	8.28e-06	5.39e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—colon cancer	8.13e-06	5.29e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—colon cancer	8.12e-06	5.28e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NRAS—colon cancer	8.03e-06	5.22e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARG—colon cancer	7.98e-06	5.19e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	7.9e-06	5.14e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT1—colon cancer	7.7e-06	5.01e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—colon cancer	7.67e-06	4.99e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MYC—colon cancer	7.48e-06	4.87e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—colon cancer	7.46e-06	4.85e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—EGFR—colon cancer	7.31e-06	4.76e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—colon cancer	7.31e-06	4.76e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARG—colon cancer	7.27e-06	4.73e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—EP300—colon cancer	7.18e-06	4.68e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KRAS—colon cancer	6.91e-06	4.5e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—EP300—colon cancer	6.76e-06	4.4e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	6.75e-06	4.4e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—EP300—colon cancer	6.75e-06	4.39e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PIK3CA—colon cancer	6.69e-06	4.36e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—EP300—colon cancer	6.38e-06	4.15e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PIK3CA—colon cancer	6.35e-06	4.13e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—colon cancer	6.27e-06	4.08e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARG—colon cancer	6.21e-06	4.04e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—colon cancer	5.87e-06	3.82e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—colon cancer	5.72e-06	3.72e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—colon cancer	5.47e-06	3.56e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PIK3CA—colon cancer	5.31e-06	3.46e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—EP300—colon cancer	5.22e-06	3.4e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—colon cancer	5.18e-06	3.37e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PIK3CA—colon cancer	5e-06	3.26e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PIK3CA—colon cancer	4.99e-06	3.25e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—colon cancer	4.89e-06	3.18e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—EP300—colon cancer	4.76e-06	3.1e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PIK3CA—colon cancer	4.72e-06	3.07e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—colon cancer	4.34e-06	2.83e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—colon cancer	4.09e-06	2.66e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—colon cancer	4.08e-06	2.65e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—EP300—colon cancer	4.07e-06	2.65e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PIK3CA—colon cancer	3.86e-06	2.51e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—colon cancer	3.85e-06	2.51e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PIK3CA—colon cancer	3.52e-06	2.29e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKT1—colon cancer	3.15e-06	2.05e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PIK3CA—colon cancer	3.01e-06	1.96e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—colon cancer	2.88e-06	1.87e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—colon cancer	2.46e-06	1.6e-05	CbGpPWpGaD
